The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

• Autoři: DUCREUX M.; ABOU-ALFA G. K.; BEKAII-SAAB T.; BERLIN J.; CERVANTES A.; DE BAERE T.; ENG C.; GALLE P.; GILL S.; GRUENBERGER T.; HAUSTERMANS K.; LAMARCA A.; LAURENT-PUIG P.; LLOVET J. M.; LORDICK F.; MACARULLA T.; MUKHERJI D.; MURO K.; LORDICK OBERMANNOVÁ Radka; CONNOR J-M.; REILLY E. M.; OSTERLUND P.; PHILIP P.; PRAGER G.; RUIZ-GARCIA E.; SANGRO B.; SEUFFERLEIN T.; TABERNERO J.; VERSLYPE C.; WASAN H.; VAN CUTSEM E.
• Rok publikování: 2023
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: ESMO OPEN
• Fakulta / Pracoviště MU: Lékařská fakulta
• www: https://www.sciencedirect.com/science/article/pii/S2059702923007986?via%3Dihub
• Doi: http://dx.doi.org/10.1016/j.esmoop.2023.101567
• Klíčová slova: hepatocellular carcinoma; liver transplantation; chemoembolisation; immunotherapy; radioembolisation
• Popis: This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.